| 000 | naa a22 7ar4500 | ||
|---|---|---|---|
| 005 | 20150602094728.0 | ||
| 008 | 150427t xxu||||| |||| 00| 0 tu d | ||
| 001 | 264652 | ||
| 016 | _aWOS:000347269300001 | ||
| 022 | _a0197-0186 | ||
| 040 | _aNEU | ||
| 041 | _aeng | ||
| 050 | 0 | 4 | _aWL 140 |
| 100 | 1 |
_9573261 _aYildirim, Fatos Belgin. |
|
| 245 | 1 | 0 |
_aMechanism of the beneficial effect of melatonin in experimental Parkinson's disease _cFatos Belgin Yildirim, Ozlem Ozsoy, Gamze Tanriover, Yasemin Kaya, Eren Ogut, Burcu Gemici, Sayra Dilmac, Ayse Ozkan, Aysel Agar, Mutay Aslan. |
| 260 |
_aPergamon-Elsevier Science Ltd., _c2014. |
||
| 520 | _aThis study aimed to elucidate locomotor activity changes in 6-hydroxydopamine (6-OHDA) induced Parkinson's disease (PD) and investigate the possible beneficial effects of melatonin on altered levels of locomotor activity, cyclooxygenase (COX), prostaglandin E2 (PGE2), nuclear factor kappa-B (NF-kappa B), nitrate/nitrite and apoptosis. Male Wistar rats were divided into five groups: vehicle (V), melatonin-treated (M), 6-OHDA-injected (6-OHDA), 6-OHDA-injected + melatonin-treated (6-OHDA-Mel) and melatonin treated + 6-OHDA-injected (Mel-6-OHDA). Melatonin was administered intraperitoneally at a dose of 10 mg/kg/day for 30 days in M and Mel-6-OHDA groups, for 7 days in 6-OHDA-Mel group. Experimental PD was created stereotactically via unilateral infusion of 6-OHDA into the medial forebrain bundle (MFB). The 6-OHDA-Mel group started receiving melatonin when experimental PD was created and treatment was continued for 7 days (post-treatment). In the Mel-6-OHDA group, experimental PD was created on the 23rd day of melatonin treatment and continued for the remaining 7 days (pre- and post-treatment). Locomotor activity performance decreased in 6-OHDA group compared with vehicle; however melatonin treatment did not improve this impairment. Nuclear factor kappa Bp65 and Bcl-2 levels were significantly decreased while COX, PGE2 and caspase-3 activity were significantly increased in 6-OHDA group. Melatonin treatment significantly decreased COX, PGE2 and caspase-3 activity, increased Bcl-2 and had no effect on NE-kappa B levels in experimental PD. 6-Hydroxydopamine injection caused an obvious reduction in TH positive dopaminergic neuron viability as determined by immunohistochemistry. Melatonin supplementation decreased dopaminergic neuron death in 6-OHDA-Mel and Mel-6-OHDA groups compared with 6-OHDA group. Melatonin also protected against 6-OHDA-induced apoptosis, as identified by increment in Bcl-2 levels in dopaminergic neurons. The protective effect of melatonin was more prominent for most parameter following 30 days treatment (pre- and post-) than 7 days post-treatment. In summary, melatonin treatment decreased dopaminergic neuron death in experimental PD model by increasing Bcl-2 protein level and decreasing caspase-3 activity. (C) 2014 Elsevier Ltd. All rights reserved. | ||
| 650 | 0 |
_9124265 _aNeurology |
|
| 650 | 0 |
_9572720 _aNear East University Article |
|
| 650 | 0 |
_9572723 _aYakın Doğu Üniversitesi Makale |
|
| 650 | 0 |
_9573262 _aMelatonin |
|
| 650 | 0 |
_9573263 _a6-Hydroxydopamine |
|
| 650 | 0 |
_9573264 _aCyclooxygenase |
|
| 650 | 0 |
_9573265 _a Nf-Kappa-B |
|
| 773 |
_gDEC 2014 , Vol 79, p1-11 _x01970186 _tNeurochemistry International |
||
| 856 | _uhttp://library.neu.edu.tr:2048/login?url=http://dx.doi.org/10.1016/j.neuint.2014.09.005 | ||
| 942 |
_x1000007 _kWL0000140M432014 _cOED |
||
| 999 | _c241345 | ||